Litigation Details for VIFOR (INTERNATIONAL) AG v. MYLAN LABORATORIES LTD. (D.N.J. 2020)
✉ Email this page to a colleague
VIFOR (INTERNATIONAL) AG v. MYLAN LABORATORIES LTD. (D.N.J. 2020)
| Docket | ⤷ Try a Trial | Date Filed | 2020-02-13 |
| Court | District Court, D. New Jersey | Date Terminated | 2020-02-23 |
| Cause | 35:271 Patent Infringement | Assigned To | Freda L. Wolfson |
| Jury Demand | None | Referred To | Douglas Arpert |
| Patents | 10,519,252; 7,612,109; 7,754,702; 8,895,612; 9,376,505 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in VIFOR (INTERNATIONAL) AG v. MYLAN LABORATORIES LTD.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for VIFOR (INTERNATIONAL) AG v. MYLAN LABORATORIES LTD. (D.N.J. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-02-13 | 1 | Complaint | expiration of United States Patent No. 10,519,252 (“the ʼ252 patent”). The ’252 patent is listed in FDA’s Approved…with the FDA U.S. Patent Nos. 7,612,109 (“the ʼ109 patent”); 7,754,702 (“the ʼ702 patent”); 8,895,612 (“…after that patent issued. All five patents—the ’109, ’702, ’612, ’505, ’252 patents—are currently listed…. This is an action for patent infringement arising under the patent laws of the United States, … PATENT-IN-SUIT 21. The U.S. Patent and Trademark Office (“PTO” | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
